BioSpace News Archive

Harbour BioMed (HBM), and its partners Utrecht University and Erasmus Medical Center, today announced a new research collaboration with Viroclinics-DDL and Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) that will focus on the development of a combination of a monoclonal anti

Daré Bioscience, Inc., a leader in women’s health innovation, announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health.

rMark Bio, a leader in the application of AI to accelerate innovation, collaboration, and scientific discovery for the life sciences industry, today announced the formation of its new Advisory Board.

Health Care Compliance Association (HCCA) is transitioning the Clinical Practice Compliance Conference and the Healthcare Enforcement Compliance Conference to online, interactive conferences this fall.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, provides updates regarding the following clinical trials:

Castor, a leading provider of clinical trial technology that automates the research process, today announced that it has raised $12 million in funding.

FDA Introduces New Recommendation for 2-Year Annualized Bleeding Rate (ABR) as Primary Endpoint for Ongoing Phase 3 Study 270-301 Company Committed to Working with FDA to Align on Next Steps to Obtain Approval [19-August-2020]

Verndari, Inc. Announces Publication in the Journal Vaccine of Early Data Using VaxiPatch ™ Vaccine System to Administer Flu Vaccine VaxiPatch ™ microneedle dermal patch is part of a novel vaccination system comprised of subunit antigens and adjuvants Preclinical data use of VaxiPatch™ microneedle dermal patch with proprietary vaccine showed significantly higher immune response at much smaller dose compared with an existing influenza vacci

Smart infusion pumps are medical devices used to control and deliver doses of medication by intravenous route. These devices enable physicians to deliver the correct dose without constant supervision. It allows doctors and nurses to treat patients with minimal exposure to infection.

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.